Cargando…

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma

Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL. We previously showed that glutaminolysis is associated with resistance to ibrutinib. In this study, we confi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lingzhi, Nie, Lei, Jordan, Alexa, Cai, Qingsong, Liu, Yang, Li, Yijing, Che, Yuxuan, Vargas, Jovanny, Chen, Zhihong, Leeming, Angela, Wang, Wei, Yao, Yixin, Wang, Michael, Jiang, Vivian Changying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Non-Hodgkin Lymphoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230437/ https://www.ncbi.nlm.nih.gov/pubmed/36420799 http://dx.doi.org/10.3324/haematol.2022.281538

Ejemplares similares

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database
por: Liu, Xin, et al.
Publicado: (2023)

A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas
por: Wang, Xiaoxiao, et al.
Publicado: (2022)

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
por: Wai, Cho Mar Myint, et al.
Publicado: (2022)

CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development
por: Korona, Boguslawa, et al.
Publicado: (2022)

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021)

Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
por: Torres, Armando N. Bastidas, et al.
Publicado: (2021)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation
por: Koch, Karoline, et al.
Publicado: (2022)

Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study
por: Dourthe, Marie Emilie, et al.
Publicado: (2022)

Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
por: Fisher, Kevin E., et al.
Publicado: (2022)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022)

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
por: García-Sancho, Alejandro Martín, et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022)

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
por: Veloza, Luis, et al.
Publicado: (2022)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
por: Decombis, Salomé, et al.
Publicado: (2022)

Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
por: Demel, Uta M., et al.
Publicado: (2022)

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
por: López, Cristina, et al.
Publicado: (2022)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
por: Ghione, Paola, et al.
Publicado: (2022)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation
por: Eyre, Toby A., et al.
Publicado: (2022)

Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
por: Tucci, Alessandra, et al.
Publicado: (2022)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022)

Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis
por: Moonla, Chatphatai, et al.
Publicado: (2023)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
por: Leivonen, Suvi-Katri, et al.
Publicado: (2023)

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023)

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
por: Song, Joo Y., et al.
Publicado: (2023)

Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma
por: Mularoni, Valentina, et al.
Publicado: (2023)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mm894r7uucnvav30qcjhhdgf64